MX9603316A - Enantiomerically pure dextrorotatory isomer of liarozole. - Google Patents

Enantiomerically pure dextrorotatory isomer of liarozole.

Info

Publication number
MX9603316A
MX9603316A MX9603316A MX9603316A MX9603316A MX 9603316 A MX9603316 A MX 9603316A MX 9603316 A MX9603316 A MX 9603316A MX 9603316 A MX9603316 A MX 9603316A MX 9603316 A MX9603316 A MX 9603316A
Authority
MX
Mexico
Prior art keywords
compounds
liarozole
enantiomerically pure
dextrorotatory isomer
novel
Prior art date
Application number
MX9603316A
Other languages
Spanish (es)
Inventor
Marc Gaston Venet
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX9603316A publication Critical patent/MX9603316A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

This invention relates to the novel enantiomerically pure dextrorotatory isomer of liarozole of formula (I) and the pharmaceutically acceptable acid addition salt forms thereof. These compounds are particularly useful in treating disorders which are characterized by an increased proliferation and/or abnormal differentiation of normal, preneoplastic or neoplastic epithelial cells. These compounds are particularly useful in the field of dermatology. Also disclosed are compositions containing said novel compounds, methods of preparing said novel compounds as well as methods of using the mentioned compounds to treat the mentioned disorders.
MX9603316A 1994-02-18 1995-02-10 Enantiomerically pure dextrorotatory isomer of liarozole. MX9603316A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94200420 1994-02-18
PCT/EP1995/000490 WO1995022540A1 (en) 1994-02-18 1995-02-10 Enantiomerically pure (+)-liarozole

Publications (1)

Publication Number Publication Date
MX9603316A true MX9603316A (en) 1997-02-28

Family

ID=8216652

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9603316A MX9603316A (en) 1994-02-18 1995-02-10 Enantiomerically pure dextrorotatory isomer of liarozole.

Country Status (12)

Country Link
EP (1) EP0745077A1 (en)
JP (1) JPH09508914A (en)
CN (1) CN1141042A (en)
AU (1) AU689206B2 (en)
CA (1) CA2182583A1 (en)
IL (1) IL112688A0 (en)
MX (1) MX9603316A (en)
NZ (1) NZ279227A (en)
SG (1) SG52325A1 (en)
TW (1) TW401415B (en)
WO (1) WO1995022540A1 (en)
ZA (1) ZA951343B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019991A1 (en) * 1994-12-28 1996-07-04 Janssen Pharmaceutica N.V. Benzimidazoles as inhibitors of calcitriol metabolism
EP1992228A1 (en) * 2007-05-14 2008-11-19 Bayer CropScience AG Insecticidal substituted thiourea derivatives
US9138393B2 (en) * 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) * 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders

Also Published As

Publication number Publication date
WO1995022540A1 (en) 1995-08-24
JPH09508914A (en) 1997-09-09
TW401415B (en) 2000-08-11
CN1141042A (en) 1997-01-22
CA2182583A1 (en) 1995-08-24
AU1578795A (en) 1995-09-04
EP0745077A1 (en) 1996-12-04
NZ279227A (en) 1997-11-24
IL112688A0 (en) 1995-05-26
ZA951343B (en) 1996-08-19
AU689206B2 (en) 1998-03-26
SG52325A1 (en) 1998-09-28

Similar Documents

Publication Publication Date Title
EA200201277A1 (en) SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ANOMALOUS GROWTH OF CELLS
HUT70499A (en) Fluoroalkoxybenzaldehyde derivatives and process for producing them
EA200200509A1 (en) NEW DERIVATIVES OF BENZOMIDAZOLE USED AS ANTIPROLIFERATIVE MEANS
ZA948353B (en) Novel (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
DK0726892T3 (en) (E) -20 (22) -dehydrovitamin D compounds
MXPA05006420A (en) Pyrimidine derivates for the treatment of abnormal cell growth.
EA200100135A1 (en) ALKINYL SUBSTITUTED DERIVATIVES OF QUINOLIN-2-SHE USEFUL AS ANTI-TREATMENT AGENTS
ZA975439B (en) New pyridyl alkane acid amides.
UA27749C2 (en) Substituted cyclopropylamino-1,3,5-triazines, enantiomers, racemic mixtures or non-toxic, pharmaceutically acceptable acid addition salts thereof possessing pharmacological activity and process for the preparation thereof
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
TR200000673T2 (en) Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists.
TR200000670T2 (en) Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists.
TW200502221A (en) Novel lactams and uses thereof
HK114895A (en) Use of benzimidazoles in the treatment of epithelial disorders
NZ512526A (en) 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
BG100661A (en) Aryl acetic acid derivatives
PL336640A1 (en) Substituted 3,3-diamino-2- propenonitriles, their production and application
CA2314154A1 (en) Azepine or larger medium ring derivatives and their use as pharmaceuticals
MX9603316A (en) Enantiomerically pure dextrorotatory isomer of liarozole.
IL166103A0 (en) Pyrrolidine derivatives and their use
MX9603510A (en) Enantiomerically pure(-)-liarozole.
MX9704704A (en) 4-amino-2-ureide-pyrimidin-5-carboxylic acid amides, process for the preparation thereof, medicaments containing these compounds, and their utilization.
TNSN86165A1 (en) NOVEL ORTHO-ANISAMIDES, PROCESS FOR OBTAINING THEM AND THERAPEUTIC APPLICATIONS
CA2208032A1 (en) Substituted amidinonaphthyl ester derivative
IL115004A0 (en) Use of substituted 6-amino-4h-pyrans as medicaments, certain novel such compounds and their preparation